A phase I, first-in-human, safety trial of AT-1501 in healthy volunteers and patients with Amyotrophic Lateral Sclerosis (ALS)
Phase of Trial: Phase I
Latest Information Update: 18 Nov 2019
Price : $35 *
At a glance
- Drugs AT 1501 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; Pharmacokinetics
- 18 Nov 2019 According to an Anelixis Therapeutics media release, the company plans to present data from this trial at an upcoming scientific meeting.
- 18 Nov 2019 Status changed from recruiting to completed, according to an Anelixis Therapeutics media release.
- 05 Dec 2018 New trial record